Medizinische Universität Graz - Research portal

Go directly to the nagivation.
Go directly to the content.

Navigation/Search

Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Almalki, MH; Alsuraikh, MA; Almalki, E; Aziz, F; Almazrouei, R; AlDahmani, KM; Alshahrani, F; Alaqeel, M; Mahzari, M; Ekhzaimy, A.
Impulse control disorders in patients with dopamine agonist-treated pituitary adenomas: a cross-sectional multicenter study.
Pituitary. 2024; Doi: 10.1007/s11102-024-01383-2
Web of Science PubMed FullText FullText_MUG

Co-authors Med Uni Graz: Aziz Faisal
Altmetrics:
Dimensions Citations:
Plum Analytics:
Scite (citation analytics):
Abstract:: BACKGROUND: Impulse control disorders (ICDs) have been described as underrecognized side effects of dopamine agonists (DAs) in neurological disorders but are not sufficiently understood in endocrine conditions. OBJECTIVE: To identify the prevalence of DAs induced ICDs and determine potential risk factors related to these disorders in patients with prolactinoma and non-function pituitary adenomas (NFPAs). METHODS: This is a cross-sectional multicenter study involving 200 patients with prolactinoma and NFPAs, who received follow-ups in tertiary referral centers. DA-induced ICDs were assessed using ICD questionnaires modified from prior studies. RESULT: At least one ICD was reported by 52% of participants, among whom 28.5% mentioned compulsive shopping, 24.5% punding, and 24.5% hypersexuality. Furthermore, 33% of the patients reported the presence of one type of ICD behavior, while 12% specified two and 7% had three types of such behavior. The multivariable logistic regression showed that the significant risk factors of ICD were younger age (adjusted odds ratio [AOR]: 0.92, 95% confidence interval [CI]: 0.88-0.97, p 0.001), not being unmarried or single (AOR: 0.15, 95%CI: 0.03-0.84, p 0.03), and a positive history of psychiatric illness (AOR: 7.67, 95% CI: 1.37-42.97, p 0.021). CONCLUSION: ICDs with a broad range of psychiatric symptoms are common in individuals with DA-treated prolactinoma and NFPAs. Endocrinologists should be aware of this potential side effect, particularly in patients and those a personal history of psychiatric disorder.
Find related publications in this database (Keywords): Dopamine agonist; Impulse control disorders; Pituitary tumors; Prolactinoma; Cabergoline; Bromocriptine; ICD questionnaires